12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IDX19368: FDA hold

Idenix said FDA placed a clinical hold on IDX19368, which was slated to start human testing this quarter. According to Idenix, the agency placed the hold as a precautionary measure following cardiac and renal safety concerns in a Phase II trial of a similar NS5B inhibitor from Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.). Last...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >